HOME >> BIOLOGY >> NEWS
Study Shows Aspirin Blocks "Plant Pain"

It's not news anymore that plants may "cry in pain" when attacked or damaged by a hungry herbivore, but now we know that there is a way to stop all this vegetable "suffering" right in your medicine cabinet -- with simple aspirin.

Plants may not feel the pain of an injury as animals do, but they do have their own "alarm" reaction to tissue damage and, in an effect curiously similar to that in animals, this reaction can be short-circuited by aspirin and other similar drugs, according to a study recently published in The Journal of Biological Chemistry.

The study was authored by plant biologists Zhiqiang Pan of Arizona State University; Bilal Camara of the Institut de Biologie Moleculaire des Plantes, Strasbourg, France; Harold W. Gardner of the United States Department of Agriculture; and Ralph A. Backhaus of Arizona State University and appeared in JBC's July 17 issue.

Aspirin, the researchers discovered, interrupts the production of a key compound that plants produce in response to physical injury in much the same way that it interrupts in animals the production of the compound that tissue produces when it is hurt, leading to the pain reaction.

The function of aspirin in animals is to block the production of prostaglandin, which triggers swelling and pain. Aspirin binds to the active site of the enzyme that is critical to producing prostaglandin.

"It essentially renders the enzyme dead and prevents prostaglandins from building up and creating a reaction," said Backhaus.

In plants, aspirin blocks the production of jasmonic acid by similarly binding a critical enzyme.

"Jasmonic acid is a hormone that is made when plants are in distress. It signals the production of plant-defense compounds -- it works a little like a shot of pain, warning the plant that it is under attack. It can also volatilize and warn nearby plants, a chain reaction that's like a warning signal to other plants. This seems to particularly apply to insect attack, as the
'"/>

Contact: James Hathaway
hathaway@asu.edu
602-965-6375
Arizona State University
31-Jul-1998


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Shows Aspirin Blocks Plant Pain

(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: